Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026
Same author

Peripheral microRNA signature in genetic frontotemporal dementia-findings from the GENFI initiative.

GeroScience·2026
Same author

A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions.

Nature genetics·2026
Same author

CSF protein biomarkers are associated with atrophy and symptom severity in genetic FTD: a GENFI study.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Composite grey matter fingerprints for genetic frontotemporal dementia.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Individualized Atrophy-Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed-Effects Modeling.

Annals of neurology·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Rhian S Convery1, Lucy L Russell1, Kerala L Adams-Carr1

  • 1Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

前性痴呆症早期检测 (EDoF) 计划使用像Ignite应用程序这样的数字工具,在前症状突变携带者中发现前性痴呆症 (FTD) 的早期迹象. 这些数字生物标志物对早期诊断和改善临床试验准备有希望.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经科学是一个神经科学.
  • 数字健康数字健康
  • 生物标志物发现发现

背景情况:

  • 前性痴呆症 (FTD) 由于其潜伏性发作,提出了诊断上的挑战.
  • 早期检测对于及时干预和有效的临床试验设计至关重要.
  • 前性痴呆症早期检测 (EDoF) 计划旨在利用新的数字工具来应对这些挑战.

研究的目的:

  • 为了确定FTD早期诊断的敏感数字生物标志物.
  • 评估Ignite应用程序和其他数字工具在检测前症状FTD突变载体中的认知和运动障碍方面的实用性.
  • 通过制定强有力的结果措施,提高对FTD的临床试验准备.

主要方法:

  • 多模式评估包括 Ignite 数字认知应用程序,语音分析,可穿戴传感器 (Fitbit,IMU 加速度计),点击测试,表面电磁图像和被动认知评估 (眼睛跟踪,通过长寿应用程序反应时间).
  • 使用了GENetic Frontotemporal Dementia Initiative (GENFI) 研究队列,包括C9orf72,GRN,MAPT突变的症状前携带者和突变负对照.
  • 在健康对照中验证了Ignite应用程序,随后将其应用于GENFI研究群体.

主要成果:

  • 该Ignite应用程序展示了检测无症状FTD突变载体 (CDR+NACC-FTLD-NM全球得分为0) 的认知障碍的能力,特别是在执行功能,处理速度和社会认知方面.
  • 初步数据表明,该应用程序有可能成为FTD的症状前生物标志物.
  • 各种数字工具在检测FTD相关的细微语音,运动和认知变化方面表现有希望.

结论:

  • 启动应用程序是一个有前途的数字认知生物标志物,用于早期FTD检测.
  • 多模式数字健康方法显示出提高FTD诊断和了解疾病进展的巨大潜力.
  • 在更大的队列中进一步验证和纳入临床实践对于常规使用和改善试验准备是必不可少的.